John W Davis
John W Davis
Editorial
BJUI compass. 2021 Jan 26;2(1):3-6. DOI:10.1002/bco2.66 2021
Low-Dose-Rate Prostate Brachytherapy (LDR-PB) adopts postsurgical PSA value for definition of cure [0.03%]
低剂量率前列腺 brachytherapy(LDR-PB)采用术后PSA值定义治愈标准
Jennifer Uribe,Santiago Uribe-Lewis,Sara Khaksar et al.
Jennifer Uribe et al.
Editorial
BJUI compass. 2020 Oct 19;2(1):9-10. DOI:10.1002/bco2.49 2020
A lower psoas muscle index predicts a poorer prognosis in metastatic hormone-naïve prostate cancer [0.03%]
更低的腰大肌指数预测转移性未接受荷尔蒙治疗前列腺癌预后不佳
Genta Iwamoto,Takashi Kawahara,Toshitaka Miyai et al.
Genta Iwamoto et al.
Introduction: A recent investigation revealed that sarcopenia was associated with a poorer prognosis in some solid malignancies, including prostate cancer. In most reports, sarcopenia was defined as a low psoas volume on ...
Prognosis and safety of radium-223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration-resistant prostate cancer: Real-world data of Japanese patients [0.03%]
同时使用镭-223与醋酸阿比特龙或恩杂鲁玛 behand治疗转移性去势抵抗性前列腺癌的预后和安全性：日本患者的现实数据
Yasuhide Miyoshi,Masato Yasui,Sohgo Ttsutsumi et al.
Yasuhide Miyoshi et al.
Objectives: To evaluate the real-world data on the efficacy and safety of a combination therapy with radium-223 (Ra-223) and second-generation androgen-receptor targeting agents (ARTAs), including abiraterone acetate (ABI...
The role of URO17™ biomarker to enhance diagnosis of urothelial cancer in new hematuria patients-First European Data [0.03%]
URO17™生物标志物在新发血尿患者尿路上皮癌诊断中的应用价值——欧洲首批数据报告
Nikhil Vasdev,Alexander Hampson,Samita Agarwal et al.
Nikhil Vasdev et al.
Introduction and objectives: Novel biomarker research is vital for the progression of safe and thorough diagnostic medicine. There is now a need to improve the diagnosis of bladder cancer via a noninvasive urine test whil...
Miguel Rodriguez-Homs,Janet Baack Kukreja
Miguel Rodriguez-Homs
Editorial
BJUI compass. 2021 Jan 4;2(1):7-8. DOI:10.1002/bco2.61 2021
Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management [0.03%]
前列腺导管腺癌的系统评价和Meta分析：发病情况、临床表现、预后及治疗手段综述
Nithesh Ranasinha,Altan Omer,Yiannis Philippou et al.
Nithesh Ranasinha et al.
Context: Ductal adenocarcinoma (DAC) is relatively rare, but is nonetheless the second most common subtype of prostate cancer. First described in 1967, opinion is still divided regarding its biology, prognosis, and outcom...
FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma [0.03%]
FGFR2/3基因改变与转移性尿路上皮癌对恩沃卢单抗治疗的反应关系研究
Elio Adib,Talal El Zarif,Rohit K Jain et al.
Elio Adib et al.
Enfortumab Vedotin (EV) is approved for metastatic urothelial carcinoma (mUC) progressing post-platinum and PD1/L1 inhibitor therapy. Erdafitinib is approved for post-platinum mUC with activating somatic genomic alterations (GAs) in FGFR2/3...
Outcomes of organ-sparing surgery for adult testicular tumors: A systematic review of the literature [0.03%]
成人睾丸肿瘤保留器官手术的疗效：文献系统回顾
Jesse Ory,Udi Blankstein,Daniel C Gonzalez et al.
Jesse Ory et al.
Objective: To perform a systematic review on the effects of testicular sparing surgery (TSS) on the oncological, functional, and hormonal outcomes of adults with testicular tumors. ...
Gonadorelins adherence in prostate cancer: A time-series analysis of England's national prescriptions during the COVID-19 pandemic (from Jan 2019 to Oct 2020) [0.03%]
新冠疫情期间(2019年1月至2020年10月)英格兰全国药物使用时间序列分析：前列腺癌患者对Gonadorelin的依从性研究
Ravina Barrett,Robert Barrett,Kalyan Dhar et al.
Ravina Barrett et al.
Objective: To examine the effect of the COVID-19 pandemic on gonadorelin analogue prescription for community patients in England. Materials and methods: ...